@Article{Cieśla2007,
journal="Gastroenterology Review/Przegląd Gastroenterologiczny",
issn="1895-5770",
volume="2",
number="2",
year="2007",
title="Review paperChronic viral hepatitis \– current epidemiological, clinical and therapeutic challenge",
abstract="Despite the fact of decrease of viral hepatitis morbidity rate, the increase of chronic hepatitis type C as well as cirrhosis and hepatocellular carcinoma caused by HBV and HCV infections has been reported. We present epidemiological aspects, pathogenesis and current methods of therapeutic procedures. Interferon alpha (IFN) is a drug of choice in the treatment of chronic hepatitis B. In patients with contraindicated or unsuccessful IFN therapy, nucleoside analogues may be useful in monotherapy or in combination with nucleotide analogues. In chronic hepatitis type C combination therapy with ribavirin and Peg IFN is recommended. New drugs including inhibitors of polymerase and protease of HCV may improve the efficacy of HCV therapy. Progress in antiviral therapy should lead to decrease of morbidity and mortality of chronic viral hepatitis.",
author="Cieśla, Andrzej
and Mach, Tomasz",
pages="69--73",
url="https://www.termedia.pl/Review-paper-Chronic-viral-hepatitis-8211-current-epidemiological-clinical-and-therapeutic-challenge,41,8250,1,1.html"
}